Skip to main content

Advertisement

SpringerLink
Log in

How do Japanese gynecologists view hormone replacement therapy for survivors of endometrial cancer? Japanese Gynecologic Oncology Group (JGOG) survey

  • Original Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Background

This survey sought to determine Japanese gynecologists’ attitudes concerning administering hormone replacement therapy (HRT) for patients after surgery for endometrial cancer (EC).

Methods

Eight hundred and eighty-eight members of the Japanese Gynecologic Oncology Group (JGOG) were asked to respond to an anonymous questionnaire on the JGOG website. The survey asked whether or not HRT was to be administered when surgery was performed (including a hysterectomy and bilateral oophorectomy) to treat EC before or after menopause. If HRT was not to be administered, respondents were asked the reason why. Respondents were presented with the same hypothetical patients that were featured in a previous survey in Germany, and differences in the mindsets of Japanese and German physicians were compared.

Results

Responses from 363 individuals (response rate 40.9 %) were analyzed. Seventy-eight percent of physicians considered HRT for patients undergoing surgery before menopause. The most prevalent reason of refusal to prescribe HRT was the risk of EC recurrence. Forty-eight percent of physicians considered HRT for patients undergoing surgery after menopause. The most prevalent reasons of refusal of HRT were its limited benefit and the availability of alternative therapies. Sixty-five percent of Japanese physicians responded that they would administer HRT to patients with low risk of recurrence vs. 46 % of physicians in Germany (P < 0.0002). Forty-nine percent of Japanese physicians approved of prescribing HRT for patients with high risk of recurrence vs. 25 % of physicians in Germany (P < 0.0001).

Conclusion

Many Japanese gynecologists have a favorable attitude toward prescribing HRT after treatment of EC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Amant F, Moerman P, Neven P et al (2005) Endometrial cancer. Lancet 366(9484):491–505

    Article  PubMed  Google Scholar 

  2. Aoki D (2014) Annual report of Gynecologic Oncology Committee, Japan Society of Obstetrics and Gynecology, 2013. J Obstet Gynaecol Res 40(2):338–348

    Article  PubMed  Google Scholar 

  3. Decruze SB, Green JA (2007) Hormone therapy in advanced and recurrent endometrial cancer: a systematic review. Int J Gynecol Cancer 17(5):964–978

    Article  CAS  PubMed  Google Scholar 

  4. Kilic S, Yilmaz N, Erdogan G et al (2010) Effect of non-oral estrogen on risk markers for metabolic syndrome in early surgically menopausal women. Climacteric 13(1):55–62

    Article  CAS  PubMed  Google Scholar 

  5. Creasman WT, Henderson D, Hinshaw W et al (1986) Estrogen replacement therapy in the patient treated for endometrial cancer. Obstet Gynecol 67(3):326–330

    CAS  PubMed  Google Scholar 

  6. Lee RB, Burke TW, Park RC (1990) Estrogen replacement therapy following treatment for stage I endometrial carcinoma. Gynecol Oncol 36(2):189–191

    Article  CAS  PubMed  Google Scholar 

  7. Chapman JA, DiSaia PJ, Osann K et al (1996) Estrogen replacement in surgical stage I and II endometrial cancer survivors. Am J Obstet Gynecol 175(5):1195–1200

    Article  CAS  PubMed  Google Scholar 

  8. Suriano KA, McHale M, McLaren CE et al (2001) Estrogen replacement therapy in endometrial cancer patients: a matched control study. Obstet Gynecol 97(4):555–560

    Article  CAS  PubMed  Google Scholar 

  9. Ayhan A, Taskiran C, Simsek S et al (2006) Does immediate hormone replacement therapy affect the oncologic outcome in endometrial cancer survivors? Int J Gynecol Cancer 16(2):805–808

    Article  CAS  PubMed  Google Scholar 

  10. Barakat RR, Bundy BN, Spirtos NM et al (2006) Randomized double-blind trial of estrogen replacement therapy versus placebo in stage I or II endometrial cancer: a Gynecologic Oncology Group Study. J Clin Oncol 24(4):587–592

    Article  CAS  PubMed  Google Scholar 

  11. Hancke K, Foeldi M, Zahradnik HP et al (2010) Estrogen replacement therapy after endometrial cancer: a survey of physicians’ prescribing practice. Climacteric 13(3):271–277

    Article  CAS  PubMed  Google Scholar 

  12. Committee on Gynecologic Practice, The American College of Obstetricians and Gynecologists (2001) ACOG committee opinion: tamoxifen and endometrial cancer. Int J Gynecol Obstet 73(1):77–79

    Article  Google Scholar 

  13. Querleu D, Planchamp F, Narducci F, Institut National du Cancer; Societe Francaise d’Oncologie Gynecologique et al (2011) Clinical practice guidelines for the management of patients with endometrial cancer in France: recommendations of the Institut National du Cancer and the Société Française d’Oncologie Gynécologique. Int J Gynecol Cancer 21(5):945–950

    Article  PubMed  Google Scholar 

  14. Japan Society of Gynecologic Oncology (2013) Endometrial cancer treatment guidelines. Kanehara & CO., LTD

    Google Scholar 

  15. Rossouw JE, Anderson GL, Prentice RL, Writing Group for the Women’s Health Initiative Investigators et al (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA 288(3):321–333

    Article  CAS  PubMed  Google Scholar 

  16. Holinka CF, Hata H, Gravanis A et al (1986) Effects of estradiol on proliferation of endometrial adenocarcinoma cells (Ishikawa line). J Steroid Biochem 25(58):781–786

    Article  CAS  PubMed  Google Scholar 

  17. Farnell YZ, Ing NH (2003) The effects of estradiol and selective estrogen receptor modulators on gene expression and messenger RNA stability in immortalized sheep endometrial stromal cells and human endometrial adenocarcinoma cells. J Steroid Biochem Mol Biol 84(4):453–461

    Article  CAS  PubMed  Google Scholar 

  18. Rozenberg S, Vasquez JB (2000) Estrogen replacement therapy in patients with endometrial cancer: prescription attitude of Belgian gynecologists. Maturitas 35(2):125–128

    Article  CAS  PubMed  Google Scholar 

  19. Vavilis D, Tsolakidis D, Goulis DG et al (2011) Hormone therapy for postmenopausal endometrial cancer survivors: a survey among Greek obstetricians-gynaecologists. Eur J Gynaecol Oncol 32(1):81–83

    CAS  PubMed  Google Scholar 

  20. Lee SJ, Yeo SG, Kang SB et al (2013) Attitudes and practices of Korean gynecologists towards hormone replacement therapy in endometrial cancer survivors. Eur J Gynaecol Oncol 34(6):513–517

    CAS  PubMed  Google Scholar 

  21. Rocca WA, Grossardt BR, de Andrade M et al (2006) Survival patterns after oophorectomy in premenopausal women: a population-based cohort study. Lancet Oncol 7(10):821–828

    Article  PubMed  Google Scholar 

  22. Yoshida T, Takahashi K, Yamatani H et al (2011) Impact of surgical menopause on lipid and bone metabolism. Climacteric 14(4):445–452

    Article  CAS  PubMed  Google Scholar 

  23. Atsma F, Bartelink ML, Grobbee DE et al (2006) Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: a meta-analysis. Menopause 13(2):265–279

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

We thank all members who participated in this JGOG survey. We also thank Mr. Shigeru Honda and Ms. Aya Noguchi of the JGOG secretariat for their kind assistance.

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Hirosaki University Graduate School of Medicine, Hirosaki, Aomori, Japan

    Yoshihito Yokoyama

  2. Department of Disaster Obstetrics and Gynecology, Tohoku University Graduate School of Medicine, 2-1 Seiryo-cho, Aoba-ku, Sendai, Miyagi, 980-8573, Japan

    Kiyoshi Ito

  3. Department of Obstetrics and Gynecology, Tokyo Dental College Ichikawa General Hospital, Ichikawa, Chiba, Japan

    Kiyoshi Takamatsu

  4. Department of Gynecologic Oncology, National Hospital Organization, Shikoku Cancer Center, Matsuyama, Japan

    Kazuhiro Takehara

  5. Department of Gynecology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan

    Toru Nakanishi

  6. Department of Medical Oncology, Nippon Medical School Musashikosugi Hospital, Kawasaki, Kanagawa, Japan

    Kenichi Harano

  7. Department of Obstetrics and Gynecology, Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido, Japan

    Hidemichi Watari

  8. Department of Obstetrics and Gynecology, School of Medicine, Keio University, Shinjuku, Tokyo, Japan

    Nobuyuki Susumu & Daisuke Aoki

  9. Gynecology Service, National Hospital Organization, Kyushu Cancer Center, Fukuoka, Fukuoka, Japan

    Toshiaki Saito

Authors
  1. Yoshihito Yokoyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kiyoshi Ito
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kiyoshi Takamatsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kazuhiro Takehara
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Toru Nakanishi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kenichi Harano
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hidemichi Watari
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Nobuyuki Susumu
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Daisuke Aoki
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Toshiaki Saito
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

Disease Committee of Uterine Cancer, Japanese Gynecologic Oncology Group

Corresponding author

Correspondence to Kiyoshi Ito.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yokoyama, Y., Ito, K., Takamatsu, K. et al. How do Japanese gynecologists view hormone replacement therapy for survivors of endometrial cancer? Japanese Gynecologic Oncology Group (JGOG) survey. Int J Clin Oncol 20, 997–1004 (2015). https://doi.org/10.1007/s10147-015-0808-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-015-0808-5

Keywords

Search

Navigation